Trials / Completed
CompletedNCT02724358
Rg3 in Combination With TACE in Hepatocellular Carcinoma Patients With High Expression of Notch1
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 320 (actual)
- Sponsor
- Eastern Hepatobiliary Surgery Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
In order to provide a new option for clinical anti-angiogenesis therapy in hepatoma, a randomized controlled study is planed to confirm the effect of Rg3 in combination with TACE on angiogenesis and tumor treatment in advanced hepatocellular carcinoma patients with high expression of Notch1.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | TACE | iodized oil (5ml) + Pirarubicin (20mg) |
| DRUG | Rg3 | 20mg, BID, maintained though Month 12. |
| OTHER | TACE + Rg3 | |
| PROCEDURE | protective therapy | standard liver protective therapy |
Timeline
- Start date
- 2012-12-01
- Primary completion
- 2013-12-01
- Completion
- 2015-12-01
- First posted
- 2016-03-31
- Last updated
- 2016-03-31
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02724358. Inclusion in this directory is not an endorsement.